Infectious Diarrhea

Physician Assistant Clinics

Volumn 2, Issue 2, 2017, Pages 229-245

  Roman, Christopher ^a   Solh, Tia ^b   Broadhurst, Mary ^c  

^a BUTLER UNIVERSITY   (United States)

^b MERCER UNIVERSITY   (United States)

^c ST VINCENT HOSPITAL   (United States)

Author keywords

Campylobacter; Dehydration; Diarrhea; Norovirus; Parasites; Salmonella; Shiga toxin producing E coli; Shigella

Indexed keywords

EID: 85010483449     PISSN: 24057991     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpha.2016.12.006     Document Type: Review

References (109)

1. 1 World Health Organization. Global Health Observatory data repository. Available at: http://apps.who.int/gho/data/node.main.CODWORLD?lang=en. Accessed June 18, 2016.
2. 2 Liu, L., Johnson, H.L., Sousens, S., et al. Global, regional, and national causes of child mortality: an updated systemic analysis for 2010 with time trends since 2000. Lancet 379:9832 (2012), 2151–2161.
3. 3 Guerrant, R.L., Van Gilder, T., Steiner, T.S., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:3 (2001), 331–351.
4. 4 Garthright, W.E., Archer, D.L., Kvenberg, J.E., Estimates of incidence and costs of intestinal infectious diseases in the United States. Public Health Rep 103:2 (1988), 107–115.
5. 5 Navaneethan, U., Giannella, R.A., Mechanisms of infectious diarrhea. Nat Clin Pract Gastroenterol Hepatol 5:11 (2008), 637–647.
6. 6 King, C.K., Glass, R., Bresce, J.S., et al. Managing acute gastroenteritis among children. MMWR Recomm Rep 52:RR-16 (2003), 1–16.
7. 7 Getto, L., Zeserson, E., Breyer, M., Vomiting, diarrhea, constipation, and gastroenteritis. Emerg Med Clin North Am 29:2 (2011), 211–237.
8. 8 Freedman, S.B., Willan, A.R., Boutis, K., et al. Effect of dilute apple juice and preferred fluids vs electrolyte maintenance solution on treatment failure among children with mild gastroenteritis: a randomized clinical trial. JAMA 315:18 (2016), 1966–1974.
9. 9 Barclay, L., Park, G.W., Vega, E., et al. Infection control for norovirus. Clin Microbiol Infect 20 (2014), 731–740.
10. 10 MacCannell, T., Umscheid, C., Agarwal, R., et al. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol 32:10 (2011), 939–969.
11. 11 Hall, A.J., Lopman, B.A., Payne, D.C., et al. Norovirus disease in the United States. Emerg Infect Dis 19 (2013), 1198–1205.
12. 12 Lopman, B., Steele, D., Kirkwood, C., et al. The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Med, 13(4), 2016, e1001999 MEDLINE Complete, Ipswich, MA. Available at: http://dx.doi.org/10.1371/journal.pmed.1001999. Accessed June 15, 2016.
13. 13 Debbink, K., Lindesmith, L.C., Baric, R.S., The state of norovirus vaccines. Clin Infect Dis 58:12 (2014), 1746–1752.
14. 14 Green, K.Y., Norovirus Infection in immunocompromised hosts. Clin Microbiol Infect 20 (2014), 717–723.
15. 15 Centers for Disease Control and Prevention. 2016 Nationally notifiable conditions. Available at: https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/. Accessed June 14, 2016.
16. 16 Taylor, E.V., Herman, K.M., Ailes, E.C., et al. Common source outbreaks of Campylobacter infection in the USA, 1997-2008. Epidemiol Infect 141:5 (2013), 987–999.
17. 17 Centers for Disease Control and Prevention, Incidence and trends of infection with pathogens transmitted commonly through food—foodborne diseases and active surveillance network, 10 U.S. sites, 1996-2012. MMWR Morb Mortal Wkly Rep 62:15 (2013), 283–287.
18. 18 Blaser, M.J., Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 176:Suppl 2 (1997), S103–S105.
19. 19 Neal, K.R., Scott, H.M., Slack, R.C., et al. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. BMJ 312:7028 (1996), 414–415.
20. 20 Blaser, M.J., Engberg, J., Clinical aspects of Camplylobacter jejuni and Campylobacter coli infections. Nachamkin, I., Szymanski, C.M., Blaser, M.J., (eds.) Campylobacter, 3rd edition, 2008, ASM Press, Washington, DC, 99–122 Chapter 6.
21. 21 Nelson, J.M., Smith, K.E., Vugia, D.J., et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 190:6 (2004), 1150–1157.
22. 22 Jacobs, B.C., van Belkum, A., Endtz, H.P., Guillain-Barré syndrome and campylobacter infection. Nachamkin, I., Szymanski, C.M., Blaser, M.J., (eds.) Campylobacter, 3rd edition, 2008, ASM Press, Washington, DC, 245–262 Chapter 13.
23. 23 Nachamkin, I., Allos, B.M., Ho, T., Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev, 11(3), 1998, 555.
24. 24 Kalra, V., Chaudhry, R., Dua, T., et al. Association of Campylobacter jejuni infection with childhood Guillain-Barré syndrome: a case study. J Child Neurol 24:6 (2009), 664–668.
25. 25 Pope, J.E., Krizova, A., Garg, A.X., et al. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 117 (2007), 237–257.
26. 26 Sanders, J.W., Frenck, R.W., Putnam, S.D., et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Clin Infect Dis, 45(3), 2007, 294.
27. 27 Tribble, D.R., Sanders, J.W., Pang, L.W., et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3 day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis, 44(3), 2007, 338.
28. 28 Centers for Disease Control and Prevention. Biggest threats. Available at: http://www.cdc.gov/drugresistance/biggest_threats.html. Accessed June 8, 2016.
29. 29 Majowicz, S.E., Musto, J., Scallon, E., et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 50:6 (2010), 882–889.
30. 30 Buchwald, D.S., Blaser, M.J., A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis, 6(3), 1984, 345.
31. 31 Gill, C.J., Keene, W.E., Mohle-Boetani, J.C., et al. Alfalfa seed decontamination in a Salmonella outbreak. Emerg Infect Dis 9:4 (2003), 474–479.
32. 32 Centers for Disease Control and Prevention, Outbreak of Salmonella enteritidis infection associated with consumption of raw egg shells, 1991. MMWR Morb Mortal Wkly Rep 41:21 (1992), 369–372.
33. 33 Hennessy, T.W., Hedberg, C.W., Slutsker, L., et al. A national outbreak of Salmonella enteritidis infections from ice cream. N Engl J Med 334 (1996), 1281–1286.
34. 34 Kimura, A.C., Reddy, V., Marcus, R., et al. Chicken consumption is a newly identified risk factor for sporadic salmonella enterica serotype enteritidis infections in the United States: a case-control study in FoodNet sites. Clin Infect Dis 38:Suppl 3 (2004), S244–S252.
35. 35 Ao, T.T., Feasey, N.A., Gordon, M.A., et al. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg Infect Dis 21:6 (2015), 941–949.
36. 36 Burnett, M.W., Bass, J.W., Cook, B.A., Etiology of osteomyelitits complicating sickle cell disease. Pediatrics 101:2 (1998), 296–297.
37. 37 Acheson, D., Hohmann, E.L., Nontyphoidal salmenollosis. Clin Infect Dis 32:2 (2001), 263–269.
38. 38 Newton AE, Routh JA, Mahon BE. Typhoid & paratyphoid fever. In: CDC yellow book 2015. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/typhoid-paratyphoid-fever. Accessed June 20, 2016.
39. 39 Angulo, F.J., Tippen, S., Sharp, D.J., et al. A community waterborne outbreak of salmonellosis and the effectiveness of a boil water order. Am J Public Health 87:4 (1997), 580–584.
40. 40 Parry, C.M., Hien, T.T., Dougan, G., et al. Typhoid fever. N Engl J Med 347:2 (2002), 1770–1782.
41. 41 Hatta, M., Smits, H.L., Detection of Salmonella typhi by nested polymerase chain reaction in blood, urine, and stool samples. Am J Trop Med Hyg 76:1 (2007), 139–143.
42. 42 Crump, J.A., Luby, S.P., Mintz, E.D., The global burden of typhoid fever. Bull World Health Organ 82:5 (2004), 346–353.
43. 43 Dupont, H.L., Levine, M.M., Hornick, R.B., et al. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 159:6 (1989), 1126–1128.
44. 44 Kothary, M.H., Babu, U.S., Infective dose of foodborne pathogens in volunteers: a review. J Food Saf 21:1 (2001), 49–68.
45. 45 Scallan, E., Hoekstra, R.M., Angulo, F.J., et al. Foodborne illness acquired in the United Sates—major pathogens. Emerg Infect Dis 17:1 (2011), 7–15.
46. 46 Baker, K.S., Dallman, T.J., Ashton, P.M., et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis 15:8 (2015), 913–921.
47. 47 DuPont, H.L., Hornick, R.B., Dawkins, A.T., et al. The response of a man to virulent Shigella flexneri 2a. J Infect Dis 119:3 (1969), 296–299.
48. 48 von Seidlein, L., Kim, D.R., Ali, M., et al. A multicenter study of Shigella diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med, 3(9), 2006, e353.
49. 49 Stoll, B.J., Glass, M.I., Huq, M.U., et al. Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 146:2 (1982), 177–183.
50. 50 Echeverria, P., Sethabutr, O., Pitarangsi, C., Microbiology and diagnosis of infections with Shigella and enteroinvasive Escherichia coli. Rev Infect Dis 13:Suppl 4 (1991), S220–S225.
51. 51 Avital, A., Maayan, C., Goitein, K.J., Incidence of convulsions and encephalopathy in childhood Shigella infections. Survey of 117 hospitalized patients. Clin Pediatr (Phila) 21:11 (1982), 645–648.
52. 52 Khan, W.A., Dhar, U., Salam, M.A., et al. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics, 103(2), 1999, E18.
53. 53 Struelens, M.J., Patte, D., Kabir, I., et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 152:4 (1985), 784–790.
54. 54 Anjene, A.N., Fischer Walker, C.L., Black, R.E., Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella, and Shigella-associated reactive arthritis. J Health Popul Nutr 31:3 (2013), 299–307.
55. 55 Rahman, M., Shoma, S., Rashid, H., et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreasing susceptibility to ciprofloxacin. J Health Popul Nutr 25:2 (2007), 158–167.
56. 56 Karch, H., The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 27 (2001), 207–213.
57. 57 Picard, C., Burley, S., Bornet, C., et al. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris) 63:3 (2015), 136–143.
58. 58 Nathanson, S., Kwon, T., Elmaleh, M., et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:7 (2010), 1218–1228.
59. 59 Edelman, R., Karmali, M.A., Fleming, P.A., Summary of the international symposium and workshop on infections due to Verocytotoxin (Shiga-like-toxin)-producing Escherichia coli. J Infect Dis 157:5 (1988), 1102–1104.
60. 60 Centers for Disease Control and Prevention, Outbreak of Escherichia coli O104:H4 infections associated with sprout consumption—Europe and North America, May-July 2011. MMWR Morb Mortal Wkly Rep 62:50 (2013), 1029–1031.
61. 61 Grant, J., Wendelboe, A.M., Wendel, A., et al. Spinach-associated Escherichia coli O157:H7, Utah and Mexico, 2006. Emerg Infect Dis 14:10 (2008), 1633–1636.
62. 62 Bopp, D.J., Sauders, B.D., Waring, A.L., et al. Detection, isolation, and molecular subtyping of Escherichia coli O157:H7 and Campylobacter jejuni associated with a large waterborne outbreak. J Clin Microbiol 41:10 (2003), 174–180.
63. 63 Riley, L.W., Remis, R.S., Helgerson, S.D., et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 308 (1983), 681–685.
64. 64 Chen, J., Griffiths, M.W., Cloning and sequencing of the gene encoding universal stress protein from Escherichia coli O157:H7 isolated from Jack-in-a-Box outbreak. Lett Appl Microbiol 29:2 (1999), 103–107.
65. 65 Thorpe, C.M., Shiga toxin—producing Escherichia coli infection. Clin Infect Dis 38:9 (2004), 1298–1303.
66. 66 Rahal, E.A., Fadlallah, S.M., Nassar, F.J., et al. Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype. Front Cell Infect Microbiol, 5, 2015, 24.
67. 67 Feng, Y., Xiao, L., Zoonotic potential and molecular epidemiology of Giardia species and giardiasis. Clin Microbiol Rev 24:1 (2011), 110–140.
68. 68 Baldursson, S., Karanis, P., Waterborne transmission of protozoan parasites: review of worldwide outbreaks – an update 2004-2010. Water Res 45 (2011), 6603–6614.
69. 69 Painter, J.E., Gargano, J.W., Collier, S.A., et al. Giardiasis surveillance – United States, 2011-2012. MMWR Surveill Summ 64:3 (2015), 15–25.
70. 70 Shaw, P.K., Brodsky, R.E., Lyman, D.O., et al. A communitywide outbreak of giardiasis with evidence of transmission by a municipal water supply. Ann Intern Med 87:4 (1977), 426–432.
71. 71 Beer, K.D., Gargano, J.W., Roberts, V.A., et al. Surveillance for waterborne disease outbreaks associated with drinking water – United States, 2011-2012. MMWR Morb Mortal Wkly Rep 64:31 (2015), 842–848.
72. 72 Beer, K.D., Gargano, J.W., Roberts, V.A., et al. Outbreaks associated with environmental and undetermined water exposures – United States, 2011-2012. MMWR Morb Mortal Wkly Rep 64:31 (2015), 849–851.
73. 73 Hlavsa, M.C., Roberts, V.A., Kahler, A.M., et al. Outbreaks of illness associated with recreational water – United States, 2011-2012. MMWR Morb Mortal Wkly Rep 64:24 (2015), 668–672.
74. 74 Mintz, E.D., Hudson-Wragg, M., Mshar, P., et al. Foodborne giardiasis in a corporate office setting. J Infect Dis 167:1 (1993), 250–253.
75. 75 Quick, R., Paugh, K., Addiss, D., et al. Restaurant-associated outbreak of giardiasis. J Infect Dis 166:3 (1992), 673–676.
76. 76 Esch, K.J., Petersen, C.A., Transmission and epidemiology of zoonotic protozoal disease of companion animals. Clin Microbiol Rev 26:1 (2013), 58–85.
77. 77 Thompson, R.C.A., The zoonotic significance and molecular epidemiology of Giardia and giardiasis. Vet Parasitol 126 (2004), 15–35.
78. 78 Chute, C.G., Smith, R.P., Baron, J.A., Risk factors for endemic giardiasis. Am J Public Health 77:5 (1987), 585–587.
79. 79 Stuart, J.M., Orr, H.J., Warburton, F.G., et al. Risk factors for sporadic giardiasis: a case-control study in southwestern England. Emerg Infect Dis 9:2 (2003), 229–233.
80. 80 Ekdahl, K., Andersson, Y., Imported giardiasis: impact of international travel, immigration, and adoption. Am J Trop Med Hyg 72:6 (2005), 825–830.
81. 81 Hill, D.R., Giardiasis: issues in diagnosis and management. Infect Dis Clin North Am 7:3 (1993), 503–525.
82. 82 Chester, A.C., Macmurray, F.G., Restifo, M.D., et al. Giardiasis as a chronic disease. Dig Dis Sci 30:3 (1985), 215–218.
83. 83 Stark, D., Barratt, J.L.N., van Hal, S., et al. Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev 22:4 (2009), 634–650.
84. 84 Lengerich, E.J., Addiss, D.G., Juranek, D.D., Severe giardiasis in the United States. Clin Infect Dis 18:5 (1994), 760–763.
85. 85 Farthing, M.J., Mata, L., Urrutia, J.J., et al. Natural history of Giardia infection on infants and children in rural Guatemala and its impact on physical growth. Am J Clin Nutr 43:3 (1986), 395–405.
86. 86 Berkman, D.S., Lescano, A.G., Gilman, R.H., et al. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet 359 (2002), 564–571.
87. 87 Welsh, J.D., Poley, J.R., Hensley, J., et al. Intestinal disaccharidase and alkaline phosphatase activity in giardiasis. J Pediatr Gastroenterol Nutr 3 (1984), 37–40.
88. 88 Heyworth, M.F., Diagnostic testing for Giardia infections. Trans R Soc Trop Med Hyg 108:3 (2014), 123–125.
89. 89 Garcia, L.S., Shimizu, R.Y., Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J Clin Microbiol 35:6 (1997), 1526–1529.
90. 90 Rossignol, J.F., Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol 124 (2010), 45–53.
91. 91 Gardner, T.B., Hill, D.R., Treatment of giardiasis. Clin Microbiol Rev 14:1 (2001), 114–128.
92. 92 Huang, D.B., Clinton White, A., An updated review on cryptosporidium and giardia. Gastroenterol Clin North Am 35 (2006), 291–314.
93. 93 Navin, T.R., Cryptosporidiosis in humans: review of recent epidemiologic studies. Eur J Epidemiol 1:2 (1985), 77–83.
94. 94 Painter, J.E., Hlava, M.C., Collier, S.A., et al. Cryptosporidiosis surveillance – United States, 2011-2012. MMWR Surveill Summ 64:3 (2015), 1–13.
95. 95 Yoder, J.S., Harral, C., Beach, M.J., Cryptosporidiosis surveillance – United States, 2006-2008. MMWR Surveill Summ 59 (2010), 1–14.
96. 96 MacKenzie, W.R., Schell, W.L., Blair, K.A., et al. Massive outbreak of waterborne cryptosporidium infection in Milwaukee, Wisconsin: recurrent of illness and risk of secondary transmission. Clin Infect Dis 21:1 (1995), 57–62.
97. 97 Fayer, R., Cryptosporidium: a water-borne zoonotic parasite. Vet Parasitol 126 (2004), 37–56.
98. 98 Sorvillo, F.J., Fujoka, K., Nahlen, B., et al. Swimming-associated cryptosporidiosis. Am J Public Health 82 (1992), 742–744.
99. 99 Millard, P.S., Gensheimer, K.F., Addiss, D.G., et al. An outbreak of cryptosporidiosis from fresh-pressed apple cider. JAMA 272 (1994), 1592–1596.
100. 100 Roy, S.L., DeLong, S.M., Stenzel, S.A., Risk factors for sporadic cryptosporidiosis among immunocompetent persons in the United States from 1999 to 2001. J Clin Microbiol 42:7 (2004), 2944–2951.
101. 101 Goh, S., Reacher, M., Casemore, D.P., et al. Sporadic cryptosporidiosis, North Cumbria, England, 1996-2000. Emerg Infect Dis 10:6 (2004), 1007–1015.
102. 102 Lendner, M., Daugschies, A., Cryptosporidium infections: molecular advances. Parasitology 141:11 (2014), 1511–1532.
103. 103 Hunter, P.R., Nichols, G., Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 15 (2002), 145–154.
104. 104 Vakil, N.B., Schwartz, S.M., Buggy, B.P., et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 334 (1996), 19–23.
105. 105 Hojlyng, N., Jensen, B.N., Respiratory cryptosporidiosis in HIV-positive patients. Lancet 1:8585 (1988), 590–591.
106. 106 Arrowood, M.J., Sterling, C.R., Comparison of conventional staining methods and monoclonal antibody-based methods for Cryptosporidium oocyst detection. J Clin Microbiol 27 (1989), 1490–1495.
107. 107 Van Lint, P., Rossen, J.W., Vermeiren, S., et al. Detection of Giardia lamblia, Cryptosporidium spp. and Entamoeba histolytica in clinical stool samples by using multiplex real-time PCR after automated DNA isolation. Acta Clin Belg 68 (2013), 188–192.
108. 108 Rossignol, J.F., Ayoub, A., Ayers, M.S., Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184:1 (2001), 103–106.
109. 109 Abubakar, I., Aliyu, S.H., Arumugam, C., et al. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol 63:4 (2007), 387–393.